Responses
Unexpected outcome (positive or negative) including adverse drug reactions
CASE REPORT
Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.